NU

Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company utilizes a proprietary structure-based drug design platform to develop small molecule inhibitors that overcome the limitations of existing treatments, such as drug resistance and off-target toxicities. Their lead programs, zidesamtinib and NVL-655, are currently in clinical development for ROS1-positive and ALK-positive non-small cell lung cancer, respectively. Nuvalent aims to provide next-generation options that offer deeper and more durable clinical responses while maintaining a favorable safety profile.